Arphio is an orphan pharmaceutical company founded on the mission to improve patient access to vital treatments for rare diseases. It is estimated that it takes about seven years and visits to 10 different doctors for a patient to receive a proper diagnosis of an orphan condition. At Arphio, we partner with the best experts in the industry to identify therapeutics that are either in development or only on the market in selected countries to make them available around the globe. Arphio is founded by pharmaceutical professionals with expertise covering all major therapeutic areas and pharmaceutical forms in various parts of the globe. We are focused on rare disease detection, market access and the supply of orphan drugs internationally. Arphio is powered by DrugsIntel (DI), a data science powerhouse focusing on the aggregation, unleashing, processing, unification and deployment of pharmaceutical data covering over 75 countries, and over 6,000 sources. Our intelligence tools ensure the successful launch of orphan drugs in the market of operation, based on DI’s unique methodology of these Six factors and Pillars.